94 results
8-K
EX-99.1
REPL
Replimune Group Inc
26 Mar 24
Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions
7:33am
and execution in both U.S. and global markets. He has been involved in more than eight product launches in various roles of increasing responsibility across
8-K
REPL
Replimune Group Inc
26 Mar 24
Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions
7:33am
head for lung, skin, tumor agnostic, and rare cancers at Genentech, Inc., and previously held various positions of increasing responsibility at Genentech
8-K
REPL
Replimune Group Inc
8 Jan 24
Regulation FD Disclosure
8:00am
with respect thereto. The preliminary financial estimate presented above has been prepared by and is the responsibility of management. Estimates
8-K
obgdqegixpgvo6em
19 Sep 23
Replimune Announces Appointment of Emily Hill as Chief Financial Officer
8:15am
S-3ASR
EX-5.1
vya4kirqf 5j0odfi5
3 Aug 23
Automatic shelf registration
8:45am
S-3ASR
EX-1.2
zchv85p
3 Aug 23
Automatic shelf registration
8:45am
S-3ASR
EX-4.7
0d151q8l omq48
3 Aug 23
Automatic shelf registration
8:45am
S-3ASR
w0et i5247txm
3 Aug 23
Automatic shelf registration
8:45am
8-K
j6bfn
18 May 23
Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update
8:08am
8-K
EX-1.1
o3icfm45a6s6
12 Dec 22
Replimune Announces Proposed Public Offering
5:00pm
424B5
i3i3bkz sec
12 Dec 22
Prospectus supplement for primary offering
6:03am
424B5
1xa3w
7 Dec 22
Prospectus supplement for primary offering
4:58pm
8-K
EX-99.1
4tk1sp387wihu
7 Dec 22
Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma
7:15am